Rationale and options for combination therapy in the treatment of Type 2 diabetes

Diabetologia

Volumn 46, Issue SUPPL. 1, 2003, Pages

  Van Gaal, L F ^a   De Leeuw, I H ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Combination therapy; D phenylalanine derivative; Insulin secretion enhancer; Nateglinide; Postprandial glucose; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; AMINO ACID DERIVATIVE; ANTIDIABETIC AGENT; BENZOIC ACID DERIVATIVE; BIGUANIDE DERIVATIVE; GLIBENCLAMIDE; INSULIN; METFORMIN; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ARTICLE; BODY WEIGHT DISORDER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FLATULENCE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEFICIENCY; INSULIN RESISTANCE; LIVER TOXICITY; MEAL; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT FAILURE; WEIGHT GAIN;

EID: 0038415951     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-002-0936-0     Document Type: Article

References (43)

1. Avignon A, Radauceanu A, Monnier L (1997) Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in Type 2 diabetes. Diabetes Care 20:1822-1826
2. Polonsky KS, Given BD, Hirsch LJ et al. (1988) Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 318:231-239
3. Evans AJ, Krenz AJ (2001) Insulin resistance and β-cell dysfunction as therapeutic targets in type 2 diabetes. Diabetes Obes Metab 3:219-229
4. Monnier L (2000) Is postprandial glucose a neglected cardiovascular risk factor in Type 2 diabetes? Eur J Clin Invest 30 [Suppl 2]:3-11
5. Bruce DG, Chisholm DJ, Storlien LH, Kraegen EW (1988) Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes. Diabetes 37:736-744
6. 1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 44:968-983
7. UKPDS 38 (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes. (UKPDS 38). UK Prospective Diabetes Study (UKPDS) Group. BMJ 317:703-713
8. The DECODE study group on behalf of the European Diabetes Epidemiology Group (1999) Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354:617-621
9. Okhubo Y, Kishikawa H, Araki E et al. (1995) Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117
10. Ceriello A (2000) The postprandial state and cardiovascular disease: relevance to diabetes mellitus. Diabetes Metab Res Rev 16:125-132
11. 1c level. Diabetes Care 23:1830-1834
12. Hanefeld M, Fischer S, Julius U et al. The DIS Group (1996) Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39:1577-1583
13. Khaw K-T, Wareham N, Luben R et al. (2001) Glycated haemoglobin, diabetes and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 322:1-6
14. Turner RC, Cull CA, Frighi V, Holman RR (1999) Glycemic control with diet, sulphonylurea, metformin, or insulin in patients with Type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281: 2005-2012
15. UKPDS 28 (1998) A randomized trial of efficacy of early addition of metformin in sulphonylurea-treated Type 2 diabetes. UK Prospective Diabetes Study (UKPDS) Group. Diabetes Care 21:87-92
16. UKPDS 33 (1998) Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes. UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837-853
17. UKPDS 34 (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:354-365
18. Riddle M (2000) Combining sulphonylureas and other oral agents. Am J Med 108:15S-22S
19. Inzucchi SE (2002) Oral antihyperglycemic therapy for type 2 diabetes. Scientific review. JAMA 287:360-372
20. Hermann LS, Schersten B, Bitzen PO et al. (1994) Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care: 17:1100-1109
21. Coniff RF, Shapiro JA, Seaton TB, Bray GA (1995) Multicentre, placebo controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide and tolbutamide plus acarbose in non-insulin dependent diabetes mellitus. Am J Med 98:443-451
22. Rosenstock J, Brown A, Fischer J, Jain A, Littlejohn T, Nadeau D (1998) Efficacy and safety of acarbose in metformin-treated patients with Type 2 diabetes. Diabetes Care 21:2050-2055
23. Yki-Järvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L (1992) Comparison of insulin regimens in patients with non-insulin dependent diabetes mellitus. N Engl J Med 327:1426-1433
24. Yki-Järvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M (1999) Comparison of bedtime insulin regimens in patients with Type 2 diabetes mellitus. A randomised, controlled trial. Ann Intern Med 130:389-396
25. Johnston PS, Lebovitz HE, Coniff RF et al. (1998) Advantages of alpha-glucosidase inhibition as monotherapy in elderly Type 2 diabetic patients. J Clin Endocrinol Metab 83:1515-1522
26. Hermann LS (1979) Metformin: a review of its pharmacological properties and therapeutic use. Diabetes Metab 5233-5245
27. Van Gaal L, Maislos M, Schernthaner G, Rybka J, Segal P (2001) Miglitol combined with metformin improves glycaemic control in Type 2 diabetes. Diabetes Obes Metab 3:326-331
28. Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A, The Rosiglitazone Clinical Trials Study Group (2001) Once- and twice-daily dosing with rosiglitazone improves glycemia control in patients with type 2 diabetes. Diabetes Care 24:308-315
29. Fonseca V, Rosenstock J, Patwardhan R, Salzman A (2000) Effect of metformin and rosiglitazone combination therapy in patients with Type 2 diabetes mellitus: a randomised controlled trial. JAMA 283:1695-1702
30. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL (2000) Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study, The Pioglitazone 027 Study Group. Clin Ther 22:1395-1409
31. Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL (2001) Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled trial. Am J Med 111:10-17
32. Johnson JL, Wolf SL, Kabadi UM (1996) Efficacy of insulin and sulphonylurea combination therapy in Type 2 diabetes. A meta-analysis of the randomised placebo-controlled trials. Arch Intern Med 156:259-264
33. Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R, Freed MI (2000) Rosiglitazone short-term monotherapy lowers fasting and postprandial glucose in patients with Type 2 diabetes. Diabetologia 43:278-284
34. Hanefeld M, Bouter KP, Dickinson S, Guitard C (2000) Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care 23:202-207
35. Moses R, Slobodniuk R, Boyages S et al. (1999) Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with Type 2 diabetes. Diabetes Care 22:119-124
36. Horton E, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S (2000) Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose spikes in Type 2 diabetes. Diabetes Care 23:1660-1665
37. Marre M, Van Gaal L, Usadel K-H, Ball M, Whatmough I, Guitard C (2002) Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomised trial with type 2 diabetes patients. Diabetes Obes Metab 4:177-186
38. Rosenstock J, Gatlin M, Mallows S, Bush C (2000) Nateglinide improves glycemic control alone and in combination with troglitazone in patients with Type 2 diabetes. Diabetes 49 [Suppl 1]:498
39. Raskin P, Jovanovic L, Berger S et al. (2000) Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes. Diabetes Care 23:979-983
40. Van Gaal L, Van Acker K, De Leeuw IH (2001) Repaglinide improves blood glucose control in sulphonylurea-naïve type 2 diabetes. Diabetes Res Clin Pract 53:141-148
41. De Luis DA, Aller R, Cuellar L et al. (2001) Effect of repaglinide addition to NPH insulin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 24:1844-1845
42. Seltzer HS (1989) Drug-induced hypoglycaemia: a review of 1418 cases. Endocr Metab Clin North Am 18:163-183
43. Kalbag JB, Walter YH, Nedelman JR, McLeod JF (2001) Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo. Diabetes Care 24:73-77